Drugs that contain Donepezil Hydrochloride; Memantine Hydrochloride

1. List of Namzaric drug patents

Patent Number Company Patent Title Patent Expiry Activity Alert
These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US8338485 ALLERGAN Compositions for the treatment of CNS-related conditions
Nov, 2025

(2 years from now)

US8173708 ALLERGAN Method and composition for administering an NMDA receptor antagonist to a subject
Nov, 2025

(2 years from now)

US8362085 ALLERGAN Method for administering an NMDA receptor antagonist to a subject
Nov, 2025

(2 years from now)

US8338486 ALLERGAN Methods for the treatment of CNS-related conditions
Nov, 2025

(2 years from now)

US8283379 ALLERGAN Methods and compositions for the treatment of CNS-related conditions
Nov, 2025

(2 years from now)

US8580858 ALLERGAN Compositions for the treatment of CNS-related conditions
Nov, 2025

(2 years from now)

US8329752 ALLERGAN Composition for administering an NMDA receptor antagonist to a subject
Nov, 2025

(2 years from now)

US8598233 ALLERGAN Method for administering an NMDA receptor antagonist to a subject
Nov, 2025

(2 years from now)

US8168209 ALLERGAN Method and composition for administering an NMDA receptor antagonist to a subject
Nov, 2025

(2 years from now)

US8293794 ALLERGAN Methods and compositions for the treatment of CNS-related conditions
Nov, 2025

(2 years from now)

US8329752

(Pediatric)

ALLERGAN Composition for administering an NMDA receptor antagonist to a subject
May, 2026

(3 years from now)

US8283379

(Pediatric)

ALLERGAN Methods and compositions for the treatment of CNS-related conditions
May, 2026

(3 years from now)

US8173708

(Pediatric)

ALLERGAN Method and composition for administering an NMDA receptor antagonist to a subject
May, 2026

(3 years from now)

US8362085

(Pediatric)

ALLERGAN Method for administering an NMDA receptor antagonist to a subject
May, 2026

(3 years from now)

US8598233

(Pediatric)

ALLERGAN Method for administering an NMDA receptor antagonist to a subject
May, 2026

(3 years from now)

US8168209

(Pediatric)

ALLERGAN Method and composition for administering an NMDA receptor antagonist to a subject
May, 2026

(3 years from now)

US8039009 ALLERGAN Modified release formulations of memantine oral dosage forms
Mar, 2029

(6 years from now)

US8039009

(Pediatric)

ALLERGAN Modified release formulations of memantine oral dosage forms
Sep, 2029

(6 years from now)

US8058291 ALLERGAN Methods and compositions for the treatment of CNS-related conditions
Dec, 2029

(6 years from now)

Market Authorisation Date: 23 December, 2014

Treatment: Memantine hcl/donepezil hcl combination for the treatment of moderate to severe dementia of the alzheimer's type

Dosage: CAPSULE, EXTENDED RELEASE;ORAL

How can I launch a generic of NAMZARIC before it's patent expiration?
More Information on Dosage

availability in other generic markets.

Click on the highlighted region to filter.

900+ leading pharmaceutical companies are staying up-to-date with drug patents through Pharsight

Join them to stay ahead in capturing the next drug going generic

Other things you might be interested in